Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice

Trial Profile

Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Jul 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Lung cancer; Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 25 Apr 2017 Planned End Date changed from 1 May 2024 to 1 Dec 2024.
    • 26 Sep 2016 Status changed from not yet recruiting to recruiting.
    • 01 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top